2019
Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Ambrosy AP, Stevens SR, Al‐Khalidi H, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ, Investigators O. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal Of Heart Failure 2019, 21: 373-381. PMID: 30698316, PMCID: PMC6818499, DOI: 10.1002/ejhf.1404.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexCCI scoreSurgical revascularizationEjection fractionMedical therapySTICH trialHeart failureIschemic cardiomyopathyKansas City Cardiomyopathy QuestionnaireCo-morbidity indexCoronary artery bypassCo-morbid conditionsHealth-related qualityCoronary artery diseaseRisk of deathProportional hazards modelYears of ageTreatment effectsGreater functional limitationsArtery bypassCause mortalityIschemic etiologyArtery diseaseWalk testBaseline confounders
2018
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. American Heart Journal 2018, 198: 145-151. PMID: 29653636, DOI: 10.1016/j.ahj.2018.01.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAminobutyratesBiphenyl CompoundsCardiac Output, LowCause of DeathDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug CombinationsDrug Delivery SystemsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPatient SafetyPeptide FragmentsPrognosisProspective StudiesRisk AssessmentSeverity of Illness IndexSurvival RateTetrazolesTreatment OutcomeValsartanConceptsAcute decompensated heart failureSacubitril/valsartanB-type natriuretic peptideDecompensated heart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptideEjection fractionHeart failureHospital initiationNatriuretic peptideEnd pointClass angiotensin receptor neprilysin inhibitorAngiotensin receptor neprilysin inhibitorPg/Primary efficacy end pointAmbulatory HF patientsExploratory end pointsPIONEER-HF trialEfficacy end pointReduced ejection fractionSafety end pointOpen-label treatmentIncidence of angioedemaYears of agePIONEER-HF
2016
Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction
Pokorney SD, Miller AL, Chen AY, Thomas L, Fonarow GC, de Lemos JA, Al-Khatib SM, Velazquez EJ, Peterson ED, Wang TY. Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. Circulation 2016, 135: 38-47. PMID: 27881561, DOI: 10.1161/circulationaha.116.022359.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDefibrillators, ImplantableFemaleHeart VentriclesHumansMagnetic Resonance ImagingMaleMedicareMyocardial InfarctionMyocardial RevascularizationProportional Hazards ModelsRegistriesRetrospective StudiesStroke VolumeSurvival RateTomography, X-Ray ComputedUltrasonographyUnited StatesConceptsLow ejection fractionEjection fractionICD implantationMyocardial infarctionMI admissionsRevascularization statusImplantable cardioverter-defibrillator (ICD) useACTION Registry-GWTGICD implantation ratesMultivariable Cox modelPost-MI patientsYears of ageImplantation rateCardiac functionMedicare patientsCox modelPatientsAdmissionHigher likelihoodInfarctionImplantationAssociationYearsStatusICD